Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 471 followers
Latest posts
Last updated 4 days ago
ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
4 days ago
Studies from OPERA and Trio cohorts provide further real-world evidence.
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
4 days ago
Gepotidacin could be the first in a new class of oral antibiotic...
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps
6 days ago
Depemokimab is an ultra-long-acting biologic administered once every six months
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
10 days ago
60 abstracts to be presented across broad and growing portfolio of vaccines...
Statement: Zantac (ranitidine) litigation – settlement agreements reached
10 days ago
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac...
GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
11 days ago
GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety...
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
13 days ago
At least two million doses of long-acting cabotegravir for PrEP to be...
GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion
26 days ago
Marketing authorisation in EU expected by November 2024.
Statement: Zantac (ranitidine) litigation – Russell and Hughes cases
about 1 month ago
GSK confirmed it has reached two confidential settlements in cases filed in...
Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan
about 1 month ago
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials.
Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma
about 1 month ago
Granted based on results from phase III head-to-head DREAMM-7 trial.
GSK announces positive headline data from phase II seasonal influenza mRNA vaccine programme
about 1 month ago
Data support progression to phase III clinical trials.